JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ODV 200 mg
Drug: ODV Placebo (Matching 25 mg ODV)
Drug: ODV Placebo (Matching 200 mg ODV)
Drug: ODV 125 mg
Drug: ODV Placebo (Matching 125 mg ODV)
Drug: SMV Placebo (Matching 150 mg SMV)
Drug: ODV Placebo (Matching 100 mg ODV)
Drug: ODV 100 mg
Drug: AL-335 Placebo (matching 1200 mg AL-335)
Drug: Moxifloxacin Placebo (matching 400 mg moxifloxacin)
Drug: ODV 25 mg
Drug: SMV 150 mg
Drug: AL-335 1200 mg

First Posted Date: 2017-05-16

Last Posted Date: 2017-11-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 59

Registration Number: NCT03155893

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Optimizing Clinical Screening and Management of Maternal Mental Health: Predicting Women at Risk for Perinatal Depression

Completed

Conditions: Depression

First Posted Date: 2017-05-09

Last Posted Date: 2019-07-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 298

Registration Number: NCT03144752

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59

Phase 1

Completed

Conditions: Dry Age-related Macular Degeneration

Interventions: Biological: AAVCAGsCD59

First Posted Date: 2017-05-09

Last Posted Date: 2021-04-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 17

Registration Number: NCT03144999

Locations: 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Hematological Malignancies

Interventions: Drug: Teclistamab (IV)
Drug: Teclistamab(SC)

First Posted Date: 2017-05-09

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 282

Registration Number: NCT03145181

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects, New York, New York, United States

and more 10 locations

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: JNJ-61803534
Drug: Placebo
Drug: Midazolam

First Posted Date: 2017-05-04

Last Posted Date: 2018-07-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 47

Registration Number: NCT03139500

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Erdafitinib
Drug: Fluconazole
Drug: Itraconazole

First Posted Date: 2017-05-01

Last Posted Date: 2017-09-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 54

Registration Number: NCT03135106

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rilpivirine
Drug: Rilpivirine Long-acting Parenteral Formulation

First Posted Date: 2017-04-25

Last Posted Date: 2018-08-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 110

Registration Number: NCT03127189

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: JNJ-64155806 150 mg
Drug: Ethinylestradiol/drospirenone 0.02 mg/3 mg
Drug: COCP Placebo

First Posted Date: 2017-04-24

Last Posted Date: 2017-09-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT03126097

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

An Epidemiology Study of Treatment Resistant Depression in the United States (US)

Completed

Conditions: Depressive Disorder, Treatment-Resistant

First Posted Date: 2017-04-11

Last Posted Date: 2019-03-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 200000

Registration Number: NCT03109002

A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Phase 3

Terminated

Conditions: Hepatitis C

Interventions: Drug: No Treatment

First Posted Date: 2017-04-04

Last Posted Date: 2020-05-13

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT03099135

Locations: 🇵🇱
ID Clinic, Mysłowice, Poland
🇨🇦
PerCuro Clinical Research Ltd., Victoria, British Columbia, Canada
🇵🇱
Wojewodzki Szpital Specjalistyczny im. dr Wl. Bieganskiego, Lodz, Poland

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy